A new annual vaccine jab could potentially save thousands of lives, particularly among elderly people in the UK, a recent study suggests. The vaccine targets a respiratory virus known as respiratory syncytial virus (RSV) and is being offered to individuals aged 75 and over, as well as pregnant women from 28 weeks gestation to protect both themselves and their babies.
RSV infections primarily affect the lungs and respiratory tract, causing cold-like symptoms in healthy adults and older children. However, infants, elderly individuals, premature babies, those with underlying heart or lung conditions, and individuals with weakened immune systems are at higher risk of severe RSV infection.
The study, conducted by experts at the University of Aberdeen and the MRC-University of Glasgow Centre for Virus Research, highlights the potential benefits of the RSV vaccine programme. With a projected 70% uptake among the elderly population, the vaccine could prevent around 2,800 deaths annually, as well as reduce the need for 36,000 GP consultations, 4,600 hospital admissions, and 1,000 intensive care admissions.
Professor Roy Soiza, who led the research, emphasised the importance of alleviating the healthcare burden associated with preventable infections like RSV, especially considering the strains faced by the NHS. The programme was initiated in Scotland in August and extended to England, Wales, and Northern Ireland in September, with a catch-up initiative for those aged 75 to 79.
While acknowledging potential challenges such as vaccine hesitancy, particularly among certain demographics, researchers stressed the safety and effectiveness of the RSV vaccine. They urged healthcare professionals and caregivers to promote vaccine uptake, citing an 86% effectiveness rate in preventing RSV-related lower respiratory tract infections in the year following vaccination.
The publication of this research coincides with the NHS’s push for flu vaccines and Covid-19 boosters ahead of the winter season. Vaccine appointments, available through the NHS website, app, or by phone, aim to protect vulnerable groups and reduce the burden on the healthcare system during the colder months.
Infectious diseases expert Professor Antonia Ho from the MRC-University of Glasgow Centre for Virus Research lauded the introduction of effective RSV vaccines, alongside existing influenza and Covid-19 vaccines, as a crucial step in safeguarding at-risk individuals and easing pressure on the NHS.
As the UK gears up for winter, these vaccination initiatives are poised to play a vital role in safeguarding public health and reducing the impact of respiratory viruses on individuals, especially in the older population.